Current Research
All of our current clinical trials, listed below, are in process and closed to new patients. Please check back for trials open to new patients. To learn the details of a particular trial, please click on the title. If you need more information, you can email your questions to research@rrmginc.com or call our Research Department at 707-521-3830.
BREAST
LUNG
COLORECTAL
GASTROINTESTINAL STROMAL
SOLID TUMORS
ESOPHAGEAL
PROSTATE
OVARIAN
HEAD &; NECK
MDS/AML/CMML
MELANOMA
SYMPTOM MANAGEMENT
BREAST
NSABP B-39
This research study is for women with early stage breast cancer who have had a lumpectomy. The purpose of the study is to see if partial breast radiation therapy is as effective as whole breast radiation therapy in preventing the return of the cancer to the breast tissue where the tumor was removed. Whole breast radiation therapy is approved for treatment in this early stage, partial breast radiation is not.
This research study is for pre-menopausal women. The research study is being conducted in order to determine if shutting down the ovaries in addition to hormone therapy is better than hormone therapy alone for preventing breast cancer recurrence.
NSABP B-36This research study is for women with newly diagnosed breast cancer that has not spread to the lymph nodes. The purpose of this study is to find out if 6 treatments of (5 -fluorouracil, epirubicin and cyclophosphamide) with or without the oral drug celebrex or 4 treatments of standard combination chemotherapy drugs (doxorubicin and cyclophosphamide) with or without the oral drug celebrex is more effective in preventing the spread of your cancer. The drug celebrex is also being evaluated to see if it will help prevent your cancer from coming back.
CTSU/TAILORxThis research study is for women with early-stage breast cancer that measures 1.1-5.0 cm, is ER/PR positive, node negative and HER2 negative. The purpose of this study is to find out if a new test (Oncotype DX) will be able to help doctors and their patients with early breast cancer make better treatment decisions. Patients will receive either hormonal therapy, or hormonal and chemotherapy, depending on their Recurrence Score determined by the Oncotype DX assay. The exact treatment or regimen will be decided by the doctor and the patient.
NSABP B-42This research study is for postmenopausal women who had breast cancer that was ER and/or PR positive who have been receiving hormonal therapy for at least 2 years to prevent the cancer from returning. The purpose of this study is to determine whether or not continuing hormonal therapy with Letrozole (an Aromatase Inhibitor) for 5 additional years after already taking 5 years of hormonal therapy can further reduce the chance of breast cancer recurring. Letrozole will be provided for up to 3 years to those women with less than 5 years of hormonal therapy.
NSABP BP-59This research study is for women with early-stage breast cancer. The purpose of this study is to learn if finding cancer cells in the bone marrow has any importance in predicting the time of survival after a diagnosis of breast cancer. The study will also look at 2 different methods of finding cancer cells in the bone marrow to determine if one is better than the other. A bone marrow aspiration will be performed at the time of surgery.
NSABP B-41This research study is for women with invasive HER2-positive breast cancer who have not yet had surgery to remove the tumor. The purpose of this study is to test lapatinib when given with standard breast cancer treatments. Lapatinib is a new therapy for HER2-positive breast cancer. The study will look at how breast cancer tumors respond to the standard chemotherapy given with trastuzumab (Herceptin) and lapatinib before surgery compared to the standard therapy chemotherapy given with only trastuzumab and compared to the standard chemotherapy given with only lapatinib.
CALGB 40302This research study is for postmenopausal women with hormone receptor positive (ER/PR and HER2) advanced breast cancer. The purpose of this study is to determine whether a new anti-cancer drug called lapatinib can add to the clinical effects of a standard anti-estrogen drug called fulvestrant. Participants will be randomized into one of two groups: fulvestrant plus lapatinib, or fulvestrant plus placebo for a total of 8 weeks of treatment.
SWOG SO500This research study is for women with breast cancer that has spread to other parts of the body. The purpose of this study is to find out if the CellSearch blood test, which identifies tumor cells in the blood, can predict survival outcome in patients with metastatic breast cancer. It will test whether switching to another form of treatment based upon the results of the CellSearch blood test helps people live longer.
CALGB 40101This research study is for women with high-risk breast cancer that has not spread to the lymph nodes. The purpose of the study is to determine the best treatment for high-risk breast cancer with the fewest side effects. The study compares treatment with Adriamycin and Cytoxan to Taxol. All three drugs are FDA approved.
MDA 0328This research study is for patients with metastatic breast cancer and colorectal cancer. Capecitabine (also known as Xeloda) is a chemotherapy drug used to treat metastatic breast cancer and colorectal cancer. Capecitabine can cause Hand/Foot Syndrome, which causes tingling, burning, redness, flaking, swelling, blisters or small sores in the hands and feet. The purpose of this study is to determine if celecoxib will prevent or decrease the severity of Hand/Foot Syndrome in patients taking capecitabine for these cancers.
CCCWFU #97202This research study is for female breast cancer patients, before the start of adjuvant chemotherapy treatment. The purpose of the study is to determine if Co Q10 combined with Vitamin E will relieve cancer treatment-related fatigue in women receiving chemotherapy.
CTSU/MA27This research study is for postmenopausal women that have undergone surgery for their receptor positive breast cancer. The purpose of this study is to compare the ability of exemestane and anastrozole to prevent the recurrence of breast cancer and to compare their side effects. Every patient will receive one of these two drugs. This research is being done because there is still a risk of breast cancer returning after surgery. While current chemotherapy and hormone therapy are useful, we want to improve the chance that the cancer will not return and we do not know which of the drugs is better.
Back to the top
LUNG
Small-Cell Lung Cancer: No clinical trials are available at this time
Non-Small Cell Lung Cancer
SWOG S0424This is an observational research study that does not involve treatment for people with non-small cell lung cancer. The purpose of this study is to determine why women are more likely to be diagnosed with certain types of lung cancer than men are, and to see if factors other then smoking may put women at higher risk of lung cancer than men. The study also wants to understand what factors are associated with lung caner in men and women who do not smoke. Participants will be asked to complete a questionnaire and to give a blood sample and samples of your cancer tissue (obtained at your original biopsy).
SWOG S0533This research study is for participants with inoperable non-small cell lung cancer. The purpose of this study is to assess the safety of an investigational drug (Avastin/bevacizumab) combined with chemotherapy and radiation in the treatment of inoperable locally advanced lung cancer.
Back to the top
COLORECTAL
CTSU E5202This research study is for patients who have had surgery to remove Stage II colon cancer and may benefit from additional treatment to prevent recurrence. The purpose of this study is to determine if adding an investigational drug (Avastin/bevacizumab) to other chemotherapy agents (5-FU, oxaliplatin, leucovorin) is better for treating colon cancer patients, and whether it will help prevent the cancer from coming back.
SWOG 80405This research study is for patients with colon or rectal cancer that has spread and has not yet been treated. The purpose of this study is to determine whether one of the following two combinations: cetuximab plus chemotherapy, or cetuximab plus bevacizumab plus chemotherapy, is better than the combination of bevacizumab with chemotherapy. Treatment will be given over 8 weeks.
SWOG S0600This research study is for patients with colorectal cancer that has spread and has not responded to treatment including bevacizumab (Avastin). The purpose of this study is to compare the effects of not adding bevacizumab, or of adding either a lower dose or a higher dose of bevacizumab to cetuximab plus an irinotecan-based treatment.
CTSU E5204This research study is for patients with Stage II or III rectal cancer who have already received chemotherapy, radiation and surgery, and may benefit from additional treatment. The purpose of this study is to determine if adding an investigational drug (Avastin/bevacizumab) to other chemotherapy agents (5-FU, oxaliplatin, leucovorin) is better for treating rectal cancer patients, and whether it will help prevent the cancer from coming back.
MDA 0328This research study is for patients with metastatic breast cancer and colorectal cancer. Capecitabine (also known as Xeloda) is a chemotherapy drug used to treat metastatic breast cancer and colorectal cancer. Capecitabine can cause Hand/Foot Syndrome, which causes tingling, burning, redness, flaking, swelling, blisters or small sores in the hands and feet. The purpose of this study is to determine if celecoxib will prevent or decrease the severity of Hand/Foot Syndrome in patients taking capecitabine for these cancers.
NSABP R-04This is a research study for men and women with rectal cancer, newly diagnosed and who have not had surgery. Treatment includes radiation therapy with an IV infusion of 5-FU chemotherapy; radiation therapy with IV infusion of 5-FU plus IV oxaliplatin (an additional chemotherapy); radiation therapy with an oral (pill) chemotherapy drug (capecitabine); or radiation with oral capecitabine plus IV oxaliplatin. The purpose of this study is to compare the treatment of radiation therapy with capecitabine and radiation therapy with 5-FU, with and without oxaliplatin. When radiation and chemotherapy is completed, surgery will be performed a few weeks later to remove the tumor.
Back to the top
GASTROINTESTINAL STROMAL
No clinical trials are available at this time
Back to the top
SOLID TUMORS
No clinical trials are available at this time
Back to the top
ESOPHAGEAL
SWOG S0414This research study is for people with esophageal cancer that have a proven biopsy that is non- recurrent. The treatment plan is four cycles of chemotherapy and each cycle will be three weeks long with cetuximab (provided for free), cisplatin, and irinotecan. Radiation therapy begins on Day 1 of the third cycle of chemotherapy.
Back to the top
PROSTATE
CTSU/CALGB 90401This study is for men, with prostate cancer, who are no longer responding to hormone therapy and for whom the cancer has spread to other parts of the body. The study is being done to determine if the addition of bevacizumab to docetaxel and prednisone is more effective treatment and if it increases length of life. Docetaxel and prednisone are approved by the FDA for prostate cancer treatment; bevacizumab is approved by the FDA but not for treatment of prostate cancer.
Back to the top
OVARIAN
CTSU/GOG 0218This is a Phase III clinical trial for women with newly diagnosed advanced stage epithelial ovarian or primary peritoneal cancer who have cancer remaining in their peritoneal cavity after surgery and who have not yet received chemotherapy or radiation therapy for the cancer. This study compares standard chemotherapy treatment using carboplatin and paclitaxel to standard therapy (carboplatin and paclitaxel) in combination with bevacizumab. Bevacizumab is a drug that has been FDA approved for use in colon cancer. It is thought to work by blocking the effect of a protein made by tumors which can stimulate growth of tumor cells and blood vessels in and around tumors.
Back to the top
HEAD & NECK
CTSU/RTOG 0522This research study is for patients with advanced head and neck cancer. The purpose of this study is to compare the effects of radiation therapy and concurrent chemotherapy (cisplatin) with radiation therapy, chemotherapy, and cetuximab (C225) to find out which is better.
Back to the top
MDS/AML/CMML
SWOG E1905This research study is for patients with one of these types of bone marrow disorders: myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CML). The purpose of this study is to compare the effects of two treatment programs: Azacitidine, which is a drug approved for the treatment of MDS, or Azacitidine plus MS-275, an investigational drug.
Back to the top
MELANOMA
SWOG S0008This research study is for patients with high-risk melanoma. The purpose of this study is to compare the effects of high dose interferon alpha-2b alone against combination chemotherapy.
CTSU E2603This research study is for people who have melanoma that has spread or cannot be treated with surgery. The purpose of this study is to compare the effects of carboplatin and paclitaxel when given with BAY 43-9006 or placebo to find out which is better.
Back to the top
SYMPTOM MANAGEMENT
CCCWFU 97106This research study is for women who have completed cancer treatment, are disease free and who feel they are having sexual problems. The purpose of this study is to determine whether ArginMax, a nutritional supplement that contains arginine, a protein thought to relax blood vessels and get more blood to flow in blood vessels, helps improve sexual problems that may occur in women cancer survivors. Participants will be randomized to take either ArginMax or a placebo for 12 weeks of treatment.
URCC U1701This research study is for patients who are experiencing shortness of breath, or dyspnea, after receiving their first cycle of chemotherapy treatment for cancer. The purpose of this study is to determine whether an anti-anxiety drug called buspirone hydrochloride may be helpful in reducing dyspnea in people undergoing chemotherapy treatment. The study medication will be taken daily for 28 days.
URCC U1902This research study is for patients who are experiencing nausea caused by chemotherapy treatment for cancer. The purpose of this study is to determine if ginger capsules, given in addition to the current best medication to manage nausea caused by chemotherapy, can provide even better control of that nausea, and what dose of ginger works best.
URCC U3905This research study is for people who are experiencing sleep problems after having completed all of their scheduled surgery, chemotherapy and/or radiation therapy for their cancer within the last 2 to 24 months. The purpose of this study is to determine if a 4-week Hatha yoga program (2 times a week for 75 minutes per session) can provide improvement in sleep quality.
Back to the top